Increased Selenoprotein P Levels in Subjects with Visceral Obesity and Nonalcoholic Fatty Liver Disease

Abstract

BackgroundSelenoprotein P (SeP) has recently been reported as a novel hepatokine that regulates insulin resistance and systemic energy metabolism in rodents and humans. We explored the associations among SeP, visceral obesity, and nonalcoholic fatty liver disease (NAFLD).MethodsWe examined serum SeP concentrations in subjects with increased visceral fat area (VFA) or liver fat accumulation measured with computed tomography. Our study subjects included 120 nondiabetic individuals selected from participants of the Korean Sarcopenic Obesity Study. In addition, we evaluated the relationship between SeP and cardiometabolic risk factors, including homeostasis model of insulin resistance (HOMA-IR), high sensitivity C-reactive protein (hsCRP), adiponectin values, and brachial-ankle pulse wave velocity (baPWV).ResultsSubjects with NAFLD showed increased levels of HOMA-IR, hsCRP, VFA, and several components of metabolic syndrome and decreased levels of adiponectin and high density lipoprotein cholesterol than those of controls. Serum SeP levels were positively correlated with VFA, hsCRP, and baPWV and negatively correlated with the liver attenuation index. Not only subjects with visceral obesity but also those with NAFLD exhibited significantly increased SeP levels (P<0.001). In multiple logistic regression analysis, the subjects in the highest SeP tertile showed a higher risk for NAFLD than those in the lowest SeP tertile, even after adjusting for potential confounding factors (odds ratio, 7.48; 95% confidence interval, 1.72 to 32.60; P=0.007).ConclusionCirculating SeP levels were increased in subjects with NAFLD as well as in those with visceral obesity and may be a novel biomarker for NAFLD.

Variants in Genes Controlling Oxidative Metabolism Contribute to Lower Hepatic ATP Independent of Liver Fat Content in Type 1 Diabetes

“…Concentrations of FGF21, a modulator of mitochondrial oxidative phosphorylation (43), did not differ between patients and CON, in contrast to one previous study, probably due to lower age and markedly worse glycemic control of those patients (21). Also, concentrations of the hepatokine SepP, which may be increased in obesity and NAFLD (44) and interfere with insulin signaling by inhibiting phosphorylation of key mediators in energy metabolism such as protein kinase B and AMP-activated protein kinase (45), were unchanged in patients with type 1 diabetes.…”

Acute Overfeeding Does Not Alter Liver or Adipose Tissue-Derived Cytokines in Healthy Humans

“…Paradoxically, ANGPTL6 levels are elevated in patients with type 2 diabetes or metabolic syndrome [9,10] . Similarly, circulating SEPP1 is elevated in patients who are overweight and obese, or have non-alcoholic fatty liver disease, pre-diabetes and overt type 2 diabetes [11][12][13] . Whilst the liver is sensitive to changes in nutritional status, and hepatic lipid levels can fluctuate within several days of over or underfeeding [14,15] , it is unclear whether secretion of hepatokines are sensitive to acute changes in nutrition.…”

Evaluation Of The Relationship Between İnsülin Resistance And Selenoprotein P İn Patients With Polycystic Ovary Syndrome

“…[7] In a study that was an evaluation of visceral obesity using computed tomography, a correlation between visceral obesity and SeP level was observed. [32] However, some studies have demonstrated a negative correlation between SeP level, gene expression, obesity and IR. [31] In the present study we performed a correlation analysis between SeP and anthropometric parameters, and found negative correlations between SeP and waist circumference in the patient group, and also between SeP and BMI and the percentage of adipose tissue in the control group.…”